PDB7 Cost-Effectiveness Analysis of Once-Weekly Semaglutide As the Second-LINE Treatment for Type 2 Diabetes Mellitus Patients

Abstract

Authors

M.C. Yang E.C.H. Tan

Full Text Cite This Article
Back to Volume 22, Supplemental S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×